The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
Copenhagen University Hospital · Hvidovre Hospital · +37 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
187
total citations
- FWCI
- 54.46
- Percentile
- 100%
- References
- 245
Citations per year
Authors
33Topics & keywords
Keywords
- Medicine
- Hepatology
- Health care
- Inflammatory bowel disease
- Ulcerative colitis
- Productivity
- Disease
- Intensive care medicine
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GSGilead Sciences
- BBiogen
- CCelgene
- LMLeona M. and Harry B. Helmsley Charitable TrustAward: G-2108-04777
- CHCelltrion Healthcare
- EPEA Pharma Co., Ltd.
- HFHealth Foundation Limburg
- MMylan
- KKissei
- BIBoehringer Ingelheim Japan
- CCelltrion
- KPKyorin Pharmaceutical
- NNNovo Nordisk
- RARoyal Adelaide Hospital
- SShire
- VPVifor Pharma
- OPOtsuka Pharmaceutical
- TPTillotts Pharma
- MTMitsubishi Tanabe Pharma Corporation
- GGrifols
- DFDr. Falk Pharma
- NNorgine
- SCSandoz Canada
- GGenentech
- SSamsung
- AAllergan
- PJPfizer Japan
- ACAmgen Canada
- PCPfizer Canada
- ELEli Lilly Japan
- TCTakeda Canada
- ACAbbVie Canada
- JCJanssen Canada